Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000146998
Ethics application status
Approved
Date submitted
3/02/2011
Date registered
8/02/2011
Date last updated
15/05/2014
Type of registration
Retrospectively registered
Titles & IDs
Public title
Predicting the Response of Treatment in Cardiomyopathy
Query!
Scientific title
Predictors of Response to Therapy in New-Presentation Idiopathic Dilated Cardiomyopathy
Query!
Secondary ID [1]
253562
0
None
Query!
Universal Trial Number (UTN)
U1111-1119-2785
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Dilated Cardiomyopathy
261102
0
Query!
Condition category
Condition code
Cardiovascular
259235
259235
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Observational
Query!
Patient registry
Query!
Target follow-up duration
Query!
Target follow-up type
Query!
Description of intervention(s) / exposure
6-minute walk test, Minnesota Living with Heart Failure Questionnaire, NYHA classification, Cardiopulmonary exercise testing, Echocardiogram and CMR will all be performed at baseline, 6 months and 12 months. To complete all these investigations would take approximately 2 hours, at each time point. We will examine the relationship between these parameters and response to conventional heart failure therapy.
Query!
Intervention code [1]
257971
0
Not applicable
Query!
Comparator / control treatment
nil
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
262068
0
The primary aim of the project is to measure the prognostic significance of myocardial fibrosis in new presentation idiopathic dilated cardiomyopathy (DCM) using cardiac magnetic resonance (CMR).
Query!
Assessment method [1]
262068
0
Query!
Timepoint [1]
262068
0
Baseline, 6 months and 12 months
Query!
Secondary outcome [1]
273086
0
Determine the prevalence, severity and prognostic significance of inter- and intra-left ventricular mechanical dyssynchrony in new presentation DCM using advanced echocardiography techniques.
Query!
Assessment method [1]
273086
0
Query!
Timepoint [1]
273086
0
Baseline, 6 months and 12 months
Query!
Secondary outcome [2]
273087
0
Assess the utility of serum biomarkers of myocardial fibrosis, such as matrix metalloproteinases (MMPs) and the tissue inhibitors of matrix metalloproteinase (TIMPs), in the prediction of prognosis in new presentation DCM.
Query!
Assessment method [2]
273087
0
Query!
Timepoint [2]
273087
0
Baseline, 6 months and 12 months
Query!
Eligibility
Key inclusion criteria
Clinical heart failure (New York Heart Association class II - IV) on first presentation, LV ejection fraction <45% as measured by echocardiography, ventriculography, or cardiac
scintigraphy
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Standard MRI contraindications, including permanent pacemaker, implantable defibrillator,
severe claustrophobia, Significant coronary artery disease, as manifest by >70% stenosis in a major epicardial
coronary artery or the presence of a moderate or greater zone of ischaemia/infarction on
stress imaging, Concomitant valvular heart disease as a cause or central contributor to the heart failure
(excluding functional mitral regurgitation, Hypertrophic obstructive cardiomyopathy, Myocarditis, amyloidosis, sarcoidosis, uncontrolled thyroid disease, post-partum
cardiomyopathy, Renal impairment (eGFR <60ml/min) will be an exclusion criterion from the administration
of gadolinium, New York Heart Association class IV symptoms (i.e. dyspnoea at rest), and unstable
ischaemic heart disease will be exclusion criteria from cardiopulmonary exercise testing
Query!
Study design
Purpose
Screening
Query!
Duration
Longitudinal
Query!
Selection
Defined population
Query!
Timing
Prospective
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
5/07/2008
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
200
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
258428
0
Hospital
Query!
Name [1]
258428
0
Flinders Medical Center
Query!
Address [1]
258428
0
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042
Query!
Country [1]
258428
0
Australia
Query!
Primary sponsor type
Individual
Query!
Name
Professor Joseph Selvanayagam
Query!
Address
Department Cardiovascular Medicine
Flinders Medical Centre
1 Flinders Drive
BEDFORD PARK
SA 5042
Query!
Country
Australia
Query!
Secondary sponsor category [1]
257576
0
None
Query!
Name [1]
257576
0
Query!
Address [1]
257576
0
Query!
Country [1]
257576
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
260412
0
Southern Adelaide Health Service / Flinders University Human Research Ethics Committee
Query!
Ethics committee address [1]
260412
0
Human Research Ethics Southern Adelaide Health Service SA Health Room 2A221 - Inside Human Resources Flinders Medical Centre 1 Flinders Drive Bedford Park SA 5042
Query!
Ethics committee country [1]
260412
0
Australia
Query!
Date submitted for ethics approval [1]
260412
0
16/04/2008
Query!
Approval date [1]
260412
0
05/06/2008
Query!
Ethics approval number [1]
260412
0
74/08
Query!
Summary
Brief summary
Heart Failure (HF) is a leading cause of heart disease and mortality in developed countries. It is the leading reason for hospital admission among patients over 65 years and the most costly cardiovascular disorder in Western countries. A first hospital admission for HF has been shown to confer a worse prognosis than a first admission for bowel or breast cancer. The burden of HF is expected to increase in Australia due to the ageing population and improved survival from acute cardiac events. New cardiac imaging tools, such as cardiac MRI and novel applications of echocardiography (ultrasound of the heart), now permit an insight into some of the fundamental processes that underlie why some individuals don’t respond to conventional HF treatment. In particular, our research will focus on the scarring within the heart muscle, and the loss of coordination of the heart as it pumps, in perpetuating the vicious HF cycle. Furthermore, we will explore the role of a simple blood test, to measure markers of scarring from the heart, in predicting patient outcomes in the setting of a new diagnosis of HF. An understanding of these elements in the pathogenesis of cardiomyopathy will help clarify the mechanistic cascade of HF, and may thus lead to novel therapies to interrupt such an adverse process. This research may thus change the way cardiomyopathy is viewed and treated.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32168
0
Query!
Address
32168
0
Query!
Country
32168
0
Query!
Phone
32168
0
Query!
Fax
32168
0
Query!
Email
32168
0
Query!
Contact person for public queries
Name
15415
0
Kate Schwartz
Query!
Address
15415
0
Flinders Clinical Research
Level 3A
Mark Oliphant Building
Laffer Drive
BEDFORD PARK
SA 5042
Query!
Country
15415
0
Australia
Query!
Phone
15415
0
+61 8 8201 7700
Query!
Fax
15415
0
+61 8 8201 7701
Query!
Email
15415
0
[email protected]
Query!
Contact person for scientific queries
Name
6343
0
Dr Darryl Leong
Query!
Address
6343
0
University of Adelaide
C/O -
Flinders Clinical Research
Level 3A
Mark Oliphant Building
Laffer Drive
BEDFORD PARK
SA 5042
Query!
Country
6343
0
Australia
Query!
Phone
6343
0
+61 8 8201 7700
Query!
Fax
6343
0
+61 8 8201 7701
Query!
Email
6343
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF